Presented by: Chi Fai Ng MD
SH Ho Urology Centre, The Chinese University of Hong Kong

Introduction

Hugo® RAS is a new modular robotic system available for clinical usage. We would like to review our initial experience of using the system in robotic radical prostatectomy, with reference to our previous published data on da Vinci S and SP system. The result will provide insight in the adoption and learning curve of this new robotic system in centre with robotic experience. 

Materials

In May 2023, 10 patients with clinical localized prostate cancer underwent robotic radical prostatectomy by the Hugo® RAS. Information related to patient and tumour characteristic, as well as perioperative parameters were prospectively collected, and compared with our reported experience on da Vinci S and SP system. (Int J Urol 2019; 26:878-883)

 

Results

,

The median age of the 10 patients underwent Hugo® robotic prostatectomy was 68 years old, with median prostate size 43 cc and serum PSA level 9.4 ng/ml. The distribution of D’Amico low, intermediate and high-risk groups were 20%, 70% and 10% respectively. There was not significant difference in these parameters with the da Vinci S and SP patients (20 cases in these 2 groups). Table 1 showed the intraoperative and perioperative parameters. There was again no significant difference­ observed in the three groups.

Conclusion

From our initial experience of radical prostatectomy with the Hugo ® RAS, the perioperative result was comparable with the use of other da Vinci system. The experience of da Vinci robotic system could be transferred to the new modular system with short learning curve, less than 10 cases.

Funding

Hong Kong UGC Research Matching Fund 8601526

Lead Authors

Chi Hang Yee, MD
SH Ho Urology Centre, The Chinese University of Hong Kong

Co-Authors

Franco Lai, BN
SH Ho Urology Centre, The Chinese University of Hong Kong

Steven Leung, MSc
SH Ho Urology Centre, The Chinese University of Hong Kong

Jeremy Teoh, FRCS Ed (Urol)
SH Ho Urology Centre, The Chinese University of Hong Kong

Peter Chiu, PhD
SH Ho Urology Centre, The Chinese University of Hong Kong